Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage - Archive ouverte HAL Access content directly
Journal Articles Journal of Neurology, Neurosurgery and Psychiatry Year : 2018

Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage

, , , , , , , , , (1) , , , , , ,
1
Olivier Bousiges
  • Function : Author
Stephanie Bombois
Susanna Schraen
  • Function : Author
David Wallon
  • Function : Author
Muriel Muraine Quillard
  • Function : Author
Audrey Gabelle
Sylvain Lehmann
Claire Paquet
  • Function : Author
Elodie Amar-Bouaziz
  • Function : Author
Eloi Magnin
Carole Miguet-Alfonsi
  • Function : Author
Xavier Delbeuck
  • Function : Author
Thomas Lavaux
  • Function : Author
Pierre Anthony
  • Function : Author
Nathalie Philippi
  • Function : Author
Frederic Blanc
  • Function : Author

Abstract

Background Differential diagnosis between dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD) is not straightforward, especially in the early stages of disease. We compared AD biomarkers (phospho-Tau 181 , total-Tau, Aβ42 and Aβ40) in cerebrospinal fluid (CSF) of patients with DLB and AD, focusing especially on the prodromal stage. Methods A total of 1221 CSF were collected in different memory centres (ePLM network) in France and analysed retrospectively. Samples were obtained from patients with prodromal DLB (pro-DLB; n=57), DLB dementia (DLB-d; n=154), prodromal AD (pro-AD; n=132) and AD dementia (n=783), and control subjects (CS; n=95). These centres use the same diagnostic procedure and criteria to evaluate the patients. Results In patients with pro-DLB, CSF Aβ42 levels appeared much less disrupted than in patients at the demented stage (DLB-d) (P<0.05 CS>pro-DLB; P<0.001 CS>DLB-d). On average, Aβ40 levels in patients with DLB (pro-DLB and DLB-d) were much below those in patients with pro-AD (P<0.001 DLB groups
Not file

Dates and versions

hal-03630167 , version 1 (04-04-2022)

Identifiers

Cite

Olivier Bousiges, Stephanie Bombois, Susanna Schraen, David Wallon, Muriel Muraine Quillard, et al.. Cerebrospinal fluid Alzheimer biomarkers can be useful for discriminating dementia with Lewy bodies from Alzheimer’s disease at the prodromal stage. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89 (5), pp.467-475. ⟨10.1136/jnnp-2017-316385⟩. ⟨hal-03630167⟩

Collections

UNIV-FCOMTE
12 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More